JavaScript is disabled in your browser. You can still read and search, but features like search previews, menus, and forms may not work until it's enabled.
Skip to content
Study at a glance
AI-extracted from the abstract
Characteristics
Theoretical or philosophical paper
Peer reviewed
Intervention
novel tryptamine compounds
Topics
Depression
Key points
Proposes that novel tryptamine compounds acting as 5-HT2A agonists could be developed for treating mood disorders such as depressive disorders and bipolar disorders.
Abstract
Novel Tryptamine Compounds as 5-HT2A Agonists for Treating Mood Disorders such as Depressive Disorders and Bipolar Disorders.
Create a free account to bookmark articles, vote on relevance, generate your own syntheses, and join the discussion.
Related reading
Novel Compounds as 5-HT2A Receptor Modulators for Treating Psychiatric and Neurological Disorders.
ACS Med Chem Lett
March 13, 2025
Novel Compounds as 5-HT2A Agonists for Treating Mental Illness or CNS Disorders.
ACS Med Chem Lett
February 11, 2025
Novel Pyrrolopyridine Compounds as 5-HT2A Agonists for Treating Mental Illnesses.
ACS Med Chem Lett
January 23, 2025
Novel Non-Hallucinogenic Compounds as 5‑HT2A Agonists for Treating Mental Health Disorders, Namely Depression, Anxiety, Stress Disorders, and Eating Disorders.
ACS Med Chem Lett
August 14, 2025
Novel 5,6-Bicyclic Compounds as 5-HT2A Receptor Agonists for Treating Depression, Anxiety, Substance Abuse, and Headaches
ACS Medicinal Chemistry Letters
June 3, 2026
© 2026 The Consciousness Library
Support Our Mission
Choose your preferred way to support The Consciousness Library's work in advancing consciousness research.
Donations are processed by Mindscape Collective, our legal entity, and may appear that way on your statement.